The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
Adding immunotherapy to chemotherapy can improve survival in patients with metastatic, poorly differentiated GEP-NECs, data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback